{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:38:02Z","timestamp":1792712282284,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion Pharm Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dld.2026.09.025","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:58Z","timestamp":1792640878000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous versus intravenous double-dose infliximab for dose intensification in young adults with Crohn's disease: a prospective comparative study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-4149","authenticated-orcid":false,"given":"Tae Jong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-2070","authenticated-orcid":false,"given":"Yiyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Zi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-9867","authenticated-orcid":false,"given":"Eun Sil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-4083","authenticated-orcid":false,"given":"Mi Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.09.025_bib0001","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ibd.21152","article-title":"Natural history of Crohn's disease: comparison between childhood- and adult-onset disease","volume":"16","author":"Pigneur","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.025_bib0002","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.09.025_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.025_bib0004","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn's disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.025_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.025_bib0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2026.09.025_bib0007","first-page":"S21","article-title":"OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis","volume":"14","author":"Ben-Horin","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.09.025_bib0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5009\/gnl230291","article-title":"Effectiveness of switching to subcutaneous infliximab in ulcerative colitis patients experiencing intravenous infliximab failure","volume":"18","author":"Bae","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2026.09.025_bib0009","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.09.025_bib0010","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.025_bib0011","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000138","article-title":"Combined use of common fecal and blood markers for detection of endoscopically active inflammatory bowel disease","volume":"11","author":"Mak","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.025_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2026.09.025_bib0013","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.cgh.2019.11.056","article-title":"Histologic healing is more strongly associated with clinical outcomes in ileal Crohn's disease than endoscopic healing","volume":"18","author":"Christensen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.025_bib0014","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.025_bib0015","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.09.025_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.dld.2026.09.025_bib0017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MEG.0b013e32832bab49","article-title":"Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study","volume":"22","author":"Kallel","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.09.025_bib0018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5217\/ir.2017.15.4.434","article-title":"Medication adherence in inflammatory bowel disease","volume":"15","author":"Chan","year":"2017","journal-title":"Intest Res"},{"key":"10.1016\/j.dld.2026.09.025_bib0019","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2026.09.025_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/00365521.2019.1600014","article-title":"Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients","volume":"54","author":"Strik","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2026.09.025_bib0021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ibd\/izy217","article-title":"Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn's disease in children","volume":"25","author":"El-Matary","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2026.09.025_bib0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/ecco-jcc\/jjy155","article-title":"Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn's disease","volume":"13","author":"Kang","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.09.025_bib0023","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826009825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826009825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:44:34Z","timestamp":1792709074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826009825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S1590865826009825"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.09.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous versus intravenous double-dose infliximab for dose intensification in young adults with Crohn's disease: a prospective comparative study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}